MoonLake Immunotherapeutics (MLTX)
MLTXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$12.88
+0.0100 (+0.08%) today
At the close, Nov 12, 4:00 PM ET. Pre-market $12.88 +0.08%
- Market cap
- $1.10bn
- P/E
- –
- EPS, last 4 quarters
- $-3.67
- Dividend yield
- –
- Day range
- –
- 52-week range
- $9.46 to $23.29
- Average volume
- –
- Previous close
- $12.87
Analysts
9 coveringBuy8 buy, 1 hold, 0 sell
Targets a year out average $36.13, +180.5% from here
Earnings
next estimate $-0.8400Next report
Dec 2025
0.0%
Mar 2026
-7.7%
Jun 2026
+6.7%
Sep 2026
-20.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$65.22m | -$70.02m | -$61.66m | -$79.85m |
| Net income | -$63.02m | -$69.71m | -$61.81m | -$79.54m |
News
8 latest- MoonLake Immunotherapeutics Consensus Price Target Raised 10.66% to $35.55Fintel · 3 days ago
- MoonLake Reports Wider Q3 Loss At $79 Mln Following BLA Submission For Sonelokimab RTTNews · Nov 5, 2026
- MoonLake Immunotherapeutics Reports Third Quarter 2026 Financial Results and BLA SubmissionFintel · Nov 4, 2026
- MoonLake's Sonelokimab Meets All Endpoints In Phase 3 PsA Trial RTTNews · Aug 10, 2026
- Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?Zacks · Jul 31, 2026
- Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?Zacks · Jul 31, 2026
- MoonLake Immunotherapeutics' CFO Sells 39K SharesThe Motley Fool · Jul 3, 2026
- Why MoonLake Immunotherapeutics Stock Wilted on WednesdayThe Motley Fool · Jun 24, 2026
The company
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. MoonLake's focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis - conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- moonlaketx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.